Innovus Pharmaceuticals to Present at the 2015 Marcum Microcap Conference

San Diego, CA - May 22, 2015 - (Newswire.com)

​Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB:INNV) a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases announced today that announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel.

The Company’s presentation by Dr. Bassam Damaj, President & CEO of Innovus Pharma is scheduled to begin at 3:30 p.m. ET.

Dr. Damaj will be discussing the recent progress on:

  1. Approval and new products launches in multiple countries
  2. US Commercial growth,
  3. Launch of Androferti® in the US
  4. Additional new commercial partnerships expected in 2015
  5. Update on the approval timeline of Fluticare™ by the FDA

The annual Marcum MicroCap Conference is a showcase for public companies with less than $500 million in market capitalization. For more information or to register, please visit the conference website athttp://www.marcumllp.com/microcap

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men’s and women’s health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare™ OTC for Allergic Rhinitis.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com;www.myvesele.com; www.sensumplus.com; www.myadroferti.com

Innovus Pharma’s Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize such, and to achieve its other development, commercialization, financial and staffing objectives.  Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein.  Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC.  Copies of these reports are available from the SEC’s website or without charge from the Company.

Contact:

Kevin Holmes

Chesapeake Group

info@chesapeakegp.com

Contact Info:
Innovus Pharmaceuticals, Inc. (INNV)
Suite 440 9171 Towne Centre Drive
San Diego
CA 92122
United States

Press Release Service by Newswire.com

Original Source: Innovus Pharmaceuticals to Present at the 2015 Marcum Microcap Conference
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.